This 2011 review examines the neuropsychiatric side effects associated with centrally acting antiobesity medications. Drugs targeting monoamine systems, such as sibutramine, bupropion, and tesofensine, commonly induce insomnia but may also offer mood-enhancing benefits for patients with comorbid depression or anxiety. Agents affecting μ-opioid receptors, like naltrexone and its combination with
